Alphatec Spine Appoints New Senior Vice President of U.S. Commercial Operations

Alphatec Spine

CARLSBAD, Calif., Oct. 4, 2012 (GLOBE NEWSWIRE) -- Alphatec Holdings, Inc. (Nasdaq:ATEC), the parent company of Alphatec Spine, Inc., a medical device company that designs, develops, manufactures and markets products for the surgical treatment of spine disorders, with a focus on treating conditions related to the aging spine, announced today that Thomas McLeer has been named the Company's Senior Vice President of U.S. Commercial Operations.

As Senior Vice President of U.S. Commercial Operations, Mr. McLeer will have responsibility for U.S. Sales and Marketing, Alphatec Spine's Biologics Division and Research and Development. Mr. McLeer will report to Les Cross, the Company's Chairman and Chief Executive Officer.

Mr. McLeer most recently served as Chief Marketing Officer and General Manager of Spinal Operations for Pioneer Surgical, a full-line manufacturer and distributor of spinal implants and biologics, where he had responsibility for the Marketing, Sales, Engineering, Contracts and Customer Service departments. Prior to that, Mr. McLeer was Vice President of Sales and Marketing for Archus Orthopedics where he had responsibility for creating a global strategy focused on growth and development for a newly created spinal implant segment. Mr. McLeer has also held several other executive-level positions at Spinal Concepts, Inc., Interpore Cross, Inc., and Zimmer, Inc.

"We are pleased to have Tom join the Alphatec Spine team at this critical juncture of our growth," said Les Cross, Chairman and Chief Executive Officer of Alphatec Spine. "Tom's appointment is an important next step for the Company and its transformation into a market-driven and customer-focused organization. Integrating the teams from our U.S. commercial operations under a single point of leadership strengthens the Company's ability to deliver a continuous flow of successful new products that offer the latest in technology and deliver real value to surgeons, hospitals and patients. Tom's addition complements the progress we have already made in 2012 to prioritize our product development process and speed our time to market for new products, as well as streamline our cost structure and strengthen our margins. We look forward to Tom's contributions to help Alphatec Spine achieve its growth objectives."

Mr. McLeer received his MBA from the Kellogg School of Management and his B.S. in Business Administration with a Marketing Major from Ohio State University.

About Alphatec Spine

Alphatec Spine, Inc. is a wholly owned subsidiary of Alphatec Holdings, Inc. (Nasdaq:ATEC). Alphatec Spine is a medical device company that designs, develops, manufactures and markets products for the surgical treatment of spine disorders, primarily focused on the aging spine. The Company's mission is to combine world-class customer service with innovative, surgeon-driven products that will help improve the aging patient's quality of life. The Company is poised to achieve its goal through new solutions for patients with osteoporosis, stenosis and other aging spine deformities, improved minimally invasive products and techniques and integrated biologics solutions. In addition to its U.S. operations, the Company also markets its products in over 50 international markets through its affiliate, Scient'x S.A.S., via a direct sales force in France, Italy and the United Kingdom and via independent distributors in the rest of Europe, the Middle East and Africa. In Latin America, the Company conducts its business through its subsidiary, Cibramed Produtos Medicos. In Japan, the Company markets its products through its subsidiary, Alphatec Pacific, Inc. In the rest of Asia and Australia, the Company sells its and Scient'x's products through its and Scient'x's distributors.

The Alphatec Holdings, Inc. logo is available at

Forward Looking Statements

This press release may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainty. Such statements are based on management's current expectations and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Alphatec Spine cautions investors that there can be no assurance that actual results or business conditions will not differ materially from those projected or suggested in such forward-looking statements as a result of various factors. The words "believe," "will," "should," "expect," "intend," "estimate" and "anticipate," variations of such words and similar expressions identify forward-looking statements, but their absence does not mean that a statement is not a forward-looking statement. Forward looking statements include the Company's ability to deliver a continuous flow of successful new products that offer the latest in technology and deliver real value to surgeons, hospitals and patients; and the Company's ability to prioritize it's product development process, improve it's time to market for new products, and streamline its cost structure and strengthen its margins. The important factors that could cause actual operating results to differ significantly from those expressed or implied by such forward-looking statements include, but are not limited to: failure to achieve or maintain continued acceptance of Alphatec Spine's products by the surgeon community; failure to achieve anticipated future streamlining and cost savings initiatives related to Alphatec Spine's business; failure to successfully begin in-house manufacturing of certain products; Alphatec Spine's ability to develop and expand its U.S. and/or global revenues; continuation of favorable third party payor reimbursement for procedures performed using Alphatec Spine's products; unanticipated expenses or liabilities, including those related to the transaction described in this press release, or other adverse events affecting cash flow or Alphatec Spine's ability to successfully control its costs or achieve profitability; uncertainty of additional funding; Alphatec Spine's ability to compete with other competing products and with emerging new technologies; product liability exposure; failure to meet all financial obligations in the Cross Medical Settlement or its credit agreement; patent infringement claims and claims related to Alphatec Spine's intellectual property. Please refer to the risks detailed from time to time in Alphatec Spine's SEC reports, including its Annual Report Form 10-K for the year ended December 31, 2011, filed on March 5, 2012 with the Securities and Exchange Commission, as well as other filings on Form 10-Q and periodic filings on Form 8-K. Alphatec Spine disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, unless required by law.

CONTACT: Investor/Media Contact: Mark Francois Senior Director, Investor Relations Alphatec Spine, Inc. (760) 494-6610

Source:Alphatec Holdings, Inc.